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Gene therapy provides an efficient approach for treatment of cardiovascular disease. To realize the therapeutic
effect, both efficient delivery to the target cells and sustained expression of transgenes are required. Ultrasound
targeted microbubble destruction (UTMD) technique has become a potential strategy for target-specific gene and
drug delivery. When gene-loaded microbubble is injected, the ultrasound-mediated microbubble destruction may
spew the transported gene to the targeted cells or organ. Meanwhile, high amplitude oscillations of microbubbles
increase the permeability of capillary and cell membrane, facilitating uptake of the released gene into tissue and
cell. Therefore, efficiency of gene therapy can be significantly improved. To date, UTMD has been successfully
investigated in many diseases, and it has achieved outstanding progress in the last two decades. Herein, we discuss
the current status of gene therapy of cardiovascular diseases, and reviewed the progress of the delivery of genes to
cardiovascular system by UTMD.
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changing lifestyles, the number of people with cardiovascu-
lar diseases is increasing globally [1]. Even if recent progress
have been made in diagnosis and remedy, cardiovascular
disease remains the leading cause of mortality in many
countries [2]. Therefore, there is a strong impetus for more
effective treatment and prevention. As increasing insight
into the molecular mechanisms of cardiovascular diseases,
gene therapy has been proposed as a promising therapeutic
tool for the treatment of cardiovascular diseases [3,4].
To realize the therapeutic effect, both efficient delivery
to the target cells and sustained expression of transgenes
are required. In recent years, a large number of proof-
of-principle studies have confirmed that ultrasound
targeted microbubble destruction (UTMD) could enhance
transfection efficiency of naked plasmid DNA by several
orders of magnitude [5-7]. Therefore, it is considered as a
promising strategy for gene therapy. Herein, we discuss
the current status of gene therapy of cardiovascular dis-
eases and review the studies of gene therapy of cardiovas-
cular diseases mediated by UTMD.* Correspondence: shupingge@126.com
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diseases
To realize efficient delivery of therapeutic genes to the
cardiovascular system, a series of barriers related to al-
most all aspects of cellular biology have to be overcome.
Firstly, the gene vectors need to pass through the endo-
thelial barriers in capillary walls when systemically
injected. Meanwhile, the plasmid faces a threat of being
degraded rapidly by the immune system or DNAse in
serum before transfection. On the other hand, viral gene
vectors need to avoid the immunoreaction in circulation
and transduction of non-target organs, mainly liver and
spleen. Secondly, as gene vectors and plasma membrane
are negatively charged, the gene vectors have to diffuse
through myocardial membrane then bind to cell surface
but to be repelled from it. Thirdly, the plasmid needs to
avoid being entrapped into lysosome or the endosome,
where it will be degraded. Fourthly, the gene vector has
to penetrate the nuclear membrane to achieve the goal
of gene therapy. Nevertheless, appropriate technologies
can be used to make the gene vector itself complete tar-
get to the interested area, such as injection catheter, sur-
gical operation or UTMD [8,9]. Also directly injection of
the vector into myocardium will lead to high local con-
centration of the vector. Optimized surface of the vectortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the cell and karyon.
Current status of gene therapy of cardiovascular
disease
Nabel et al. [10] were the first to demonstrate gene ther-
apy in cardiovascular system in 1989. Since then, gene
therapeutic trials for cardiovascular diseases have been
performed all over the world. However, advances in the
area of gene therapy for cardiovascular disease are not
well satisfied because of the lack of gene delivery systems
to transfer therapeutic gene to specific target to provide
an adequate dose of a therapeutic gene [2]. So far, the
gene delivery systems are mainly divided into two kinds,
namely, viral systems and non-viral systems [11].
Viral systems derived from adeno-associated virus (AAV)
[12], retrovirus [13], lentivirus [14] and adenovirus [15] are
one of the successful gene delivery systems, which are used
in the majority of current gene therapy researches and clin-
ical trials due to their benefits of highly efficient delivery
into cells with sustained expression. Recently, Prunier et al.
[16] showed that delivering adenovirus expressing sarco-
plasmic reticulum Ca2+ ATPase (SERCA2a) into coronary
arteries could prevent ventricular arrhythmias in a ische-
mia - reperfusion model. Suckau et al. [17] also employed
adenoviral and AAV vectors to obtain high RNAi activity.
They showed that an adenoviral short hairpin RNA vector
could silence phospholamban in cardiomyocytes and im-
proved hemodynamics in heart-failure. Meanwhile, they
designed a dimeric cardiotropic AAV vector to intraven-
ously deliver RNA molecule to the heart for simplified
long-term therapy. However, viral gene therapy has been
subjected to criticism due to their potential for uncontrol-
lable and insertional mutagenesis [18]. Moreover, viral vec-
tors will evoke undesired immune response by the virtue
of systemic administration, which limits repetitive regi-
ments [19,20]. Also the transfection efficiency of viral
vectors occur with a relatively low efficiency and organ
specificity, which restricts its therapeutic efficacy [21,22].
Nonviral systems is consist of chemical methods (such
as cationic liposome, nanoparticle and polymers) and
physical methods (include gene gun, electroporation, par-
ticle bombardment, ultrasound utilization, and magne-
tofection) [23,24]. The advantages of nonviral system
include availability, cost-effectiveness, and less induction
of immune system and no limitation in size of transgenic
DNA compared with viral system, which have made them
an attractive candidate for gene delivery. Among them,
the simplest and most widely nonviral gene vector is
naked DNA. However, its transfection efficiency is limited
due to the rapid degradation by DNAse and the clearance
by the mononuclear phagocyte system in the systemic
circulation. Increasing target specificity to diseased tissue
can reduce off-target bioeffects and enhance the genetransfection efficiency. Recently, Ko et al. [25] conjugated
cell-penetrating transactivating transcriptional activator
(TAT) peptide (TATp) and/or monoclonal anti-myosin
monoclonal antibody 2G4 (mAb 2G4) which target to car-
diac myosin to liposomes for targeted gene delivery to
ischemic myocardium. The result showed that in vitro
transfection was enhanced by the presence of TATp and
was further enhanced by the additional modification with
mAb 2G4 antibody. And the transfection efficiency of
in vivo experiments was significantly enhanced in the
ischemic zone. The main disadvantage of nonviral systems
is their low transfection because of the inability of vectors
to overcome biological barriers to enter cells [26]. In other
hand, physical methods recently have been developed as a
feasible nonviral method. However, most of them are
mainly based upon invasion procedures, their inherent
risks that may outweigh their benefits, which makes them
inappropriate for cardiac gene transfer. Durieux et al. [27]
conducted a study to investigates the factors regarding
gene electrotransfer associated muscle damage, which
confirmed that gene electrotransfer associated muscle
damage was related to the intracellular presence and ex-
pression of plasmid DNA. Besides, the gene expression is
confined to the injection site. Therefore, it is necessary to
develop an effective and specific gene delivery system suit-
able for human body [28].
UTMD has been widely proved as a new strategy of
improving the delivery of drugs or genes [29,30]. Due to
its advantages of high safety profile, repetitive applicabil-
ity, cost-effectiveness and the capability to enhance the
permeability of plasma membrane to macromolecules by
its bioeffects, it is considered as a feasible tool for gene
delivery [31-35]. Chen et al. [36] have proved that
UTMD significantly increased the transfection rate of
short hairpin RNA (shRNA) vectors in vitro and in vivo,
which was equal to that of some cancer cell lines deliv-
ered by polyethylenimine (PEI). Qiu et al. [37] have
proved that enhanced green fluorescent protein (EGFP)
plasmids could be delivered effectively into rabbit Achil-
les tendons by UTMD, causing no obvious injury.
Mechanisms of UTMD in gene therapy
UTMD is an immense potential target-specific gene de-
livery tool. Its ability to elevate the gene transfection effi-
ciency in various studies in vitro and in vivo has been
confirmed [38-40], thus being consider as a promising
gene carrier approach for gene therapy. Microbubbles
(MBs) of UTMD, which may consist of lipids, albumin,
saccharide, biocompatible polymers and other materials
[41-43] are traditionally used as ultrasound contrast
agents due to their physical property of reflecting ultra-
sound. Microbubble as cavitation nucleus could expand
and contract under the effect of ultrasound, and even be
disrupted when the acoustic pressure reaches a much
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fects. The mechanism of transferring gene into cells
effectively through UTMD is based on the specific re-
sponse of the microbubbles upon exposure to ultra-
sound, namely sonoporation. Microbubbles may oscillate
when exposed to ultrasound, and then these oscillating
microbubbles may rupture. So, the gene therapy vector
incorporated with microbubbles can be released with
high local concentrations at the site of interest. Mean-
while, the destruction of MBs may transiently induce
transient holes in membranes in consequence to local
shear forces exerted on membranes by fluid flow (‘micro
streaming’) around oscillating bubbles, local shock waves
(which produce large pressure gradients across a cell), or
cavitation microjets, therefore, facilitating drug or gene
into cells [44,45], and augmenting the transfection effi-
ciency (Figure 1). The advantages of UTMD techniques
are as follows: (1) low toxicity, (2) low immunogenicity
of the vectors, (3) low invasiveness (e.g., the vector and
MB can be intravenously injected), (4) great potential for
repetitive application, and (5) organs can be targeted
with high specificity. Since UTMD can not only improve
the efficiency, but also avoid the immunogenicity, it has
been regarded as a new choice for gene therapy.
Gene therapy mediated by UTMD in
cardiovascular disease
Due to its advantages of high safety, cost effectiveness, re-
petitive applicability, and the possibility to increase the
permeability of microvessel and plasma membrane to
macromolecules by its bioeffects, ultrasound and micro-
bubble has been considered as a powerful tool in geneFigure 1 Schematic diagram of gene therapy mediated by UTMD. Mic
target tissue, resulting in sonoporation and delivery of the drug directly to
leads to transiently holes in cell membrane and capillary, which facilitates ttherapy. In recent years, many studies in vitro and in vivo
have confirmed that ultrasound and microbubble could
significantly elevate the gene transfection efficiency. It is
emerging as a potential strategy for treatment of cardio-
vascular diseases [11].
Delivery genes to cardiovascular system by microbubble
and ultrasound
Ultrasound and microbubble have been widely investi-
gated in myocardial infarctions, atherosclerosis, and in
hind limb ischemia models in rodents for therapeutic
angiogenesis. Early in the last decade, commercial and
custom microbubbles were tested for pDNA encoding
luciferase delivery in the left ventricle [46].
It has proved that TFPI-2 played an important role in
suppressing thrombosis and arterial re-stenosis, which
has been considered as a potential gene for gene therapy
of atherosclerosis. Studies have confirmed that TFPI-2
gene can be delivered to the target specifically by the
virtue of UTMD. For example, Wang et al. [39] showed
gene transfection with SonoVue and TFPI-2 gene could
suppress thrombosis and arterial re-stenosis, providing a
potential gene therapy approach for atherosclerosis.
Compared with adenovirus, the in vivo transfection effi-
ciency of SonoVue was higher than that of adenovirus
and SonoVue was less damaging when transfecting
genes into the arterial wall. Studies have confirmed that
thymosin beta 4 (TB4)-protein delivery could stimulate
differentiation of resident adult WT1-positive (WT1 is a
biomarker for development of embryonic heart and is
not normally expressed in adult rat heart) cardiac pro-
genitor cells, but its application is limited due to lowrobubbles carrying therapeutic gene are destroyed at the site of the
the target cell. The process of sonoporation induced by US application
he uptake of therapeutic gene.
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delivery of the human TB4 gene under a piggybac trans-
poson plasmid to normal rat heart. The result showed
that WT1 started to express from the nucleus of epicar-
dium layer cells one week after UTMD-TB4 treatment
(Figure 2), and the level of WT1 mRNA of which treated
with UTMD-TB4 group was 43.5-fold higher than in
normal control or UTMD-DsRed groups in the 4th
week, and c-kit mRNA level in UTMD-TB4 group was
52-fold higher after UTMD-TB4 treatment.
Chen et al. [5] have proved that the combination of
UTMD with PEI could effectively enhance transfection
efficiency of two different naked DNA without causing
any apparently side effect (Figure 3). Besides, they dem-
onstrated that naked plasmids (luciferase reporter, red
fluorescent protein reporter, EGFP) could be effectively
delivered to myocardium, combining with liposome
microbubble (MB), PEI and ultrasound (US). However,
though UTMD-mediated naked DNA in gene therapy is
effective, this technology has some limitations. TheFigure 2 Exogenous TB4 reprogrammed epicardium layer cells into W
cardiac muscle cells. A: Negative control for 12 weeks post-UTMD-DsRed;
TB4-treated rats killed at 1, 2, 3, 4 and 12 weeks after UTMD. WT1 signal fro
treatment and then migrated into myocardium layer to form new cardiac m
4 or 12 weeks after UTMD-TB4 treatment [47].parameters for this technique, including the US expos-
ure parameters, US frequency, mode of US, mechanical
index, and amount of the plasmid DNA, should be opti-
mized in the future.
Delivery viral vectors to cardiovascular system by
ultrasound and microbubble
Due to its high transfection efficiency and sustained ex-
pression, viral vector is the priority choice of transferring
genes to the target cell. However, it is difficult to restrict
the specificity of delivery in viral vectors which are usually
delivered systemically, while avoid the immunoreaction.
Additionally, the endothelial barrier limits systemic deliv-
ery of viral vector such as AAV, which leads to unsatisfac-
tory transfection efficiency. UTMD techniques have many
advantages [48]. Studies have proved that it had synergism
to combine with viral vectors, which offered many benefits
[49,50]. Firstly, the microbubbles offer the strength of site-
specific release through ultrasound irradiation, thus im-
proving viral vector specificity. And the production ofT1-positive adult cardiac progenitor cells and then formed new
B-F: The panels are high power images (scale bar = 50 mm) from
m nucleus of epicardium layer cells at 1–3 weeks after UTMD-TB4
uscle cells (WT1 signal from nucleus of cTnT-positive cells, arrows) at
Figure 3 The combination of UTMD and PEI in vivo. A, Phosphate-buffered saline group; B, phosphate-buffered saline + US; C, naked plasmid;
D, plasmid + US; E, plasmid + liposome microbubbles (LM); F, plasmid + LM + US; G, plasmid + LM + PEI; H, plasmid + LM + PEI + US. There were no
fluorescent signals in the negative control groups (A, B). When the mouse hearts exposed, the bases of the heart tissue samples had more
transfected cells than the rest of the samples (D-H). Only a few fluorescent signals could be detected in the absence of US (E). A transmural
fluorescent signal could be observed in the anterior wall after the microbubble was destroyed (F). EGFP was principally expressed in the
subendocardial layer in the absence of US(C, E, and G and arrows in G). Combining with PEI and UTMD, the distribution of EGFP was not
significant (H) [5].
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plasma membrane and capillary, thus overcoming the
endothelial barrier. Moreover, the microbubbles can sim-
ultaneously impose restriction on the immune response to
the viruses thus allowing intravascular administration and
repetitive injections [51].
Recently, a study by Naka et al. [52] demonstrated that
gene expression mediated by retrovirus was significantly
increased in all four cell types tested in this study without
any adverse bioeffecs when they were exposed for 5 s with
the ultrasound of 1.0 W/cm2. The transduction efficiencies
of ultrasound was enhanced 6.6-fold, 4.8-fold, 2.3-fold, and
3.2-fold in 293T cells, BAECs, RASMCs, and L6 cells, re-
spectively. Furthermore, in the presence of ultrasound and
the retrovirus, β-Gal activities of these cells were also in-
creased. Chen et al. [46] optimized echocardiographic pa-
rameters for successfully delivered adenoviral or plasmid
DNA to the heart. The results demonstrated that enhance-
ment of transgene expression are detected in the heart tis-
sue when treated with UTMD associating with adenoviral
or plasmid DNA. And the ultrasound parameters were
optimized with a low-transmission frequency (1.3 MHz),
maximal mechanical index, and ECG triggering to allow
completely fitting the myocardial capillary bed for micro-
bubbles dispose. In addition, Lee et al. [53] showed thatultrasonic standing wave fields could offer a potential ap-
proach to increase transduction efficiency of retrovirus-
based vector in large-scale settings.
Since, systemic administration of these viruses had
been a challenge as the drawback of adenoviral vectors
has innate host antiviral immune responses. Howard
et al. [51] have tested the ability of microbubble to load
and protect an adenoviral vector. The result demon-
strated that systemic delivery of the vector incorporated
into microbubbles led to specific targeting of the GFP
transgene. Microbubbles allow intravenous injection as
it can reduce the degradation rate of viruses by immune
system. This opens up a new therapeutic frontier for pa-
tients needs for a less invasive and highly specific gene
delivery system. Müller et al. [49] also conducted a study
to research the specificity and transfection rate of gene
delivery. In their study, adult rats were injected of
microbubbles loaded with AAV-6 or AAV-9 expressing
luciferase or EGFP. The result demonstrated that the re-
porter gene transfection efficiency significantly increased
with ultrasound exposure (Figure 4).
Also, Taylor et al. [54] carried out a study to assess
the feasibility of gene delivery system that combined
UTMD and retrovirus. In their study, they added an
envelope-deficient retroviral vector which was inherently
Figure 4 Localization of gene expression after treatment with UTMD. Adult rats were injected with microbubbles loaded with 1011 genomic
particles of AAV-9-cytomegalovirus (CMV)-MLC0.26-EGFP vectors. (A) No fluorescent signals were detectable in the absence of ultrasound; (B) The
anterior wall showed a strong fluorescent signal after UTMD; (C) When is amplified, only few fluorescent signals could be observed in the
absence of microbubbles; (D) The merged picture of green fluorescent protein (GFP)-fluorescence and phalloidin co-staining; (E) In the presence
of UTMD, multiple GFP-postive cells can be observed; (F) co-staining with phalloidin. Bar a, b: 1 mm and c ~ f: 50 μm [49].
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sound exposure of pulsed 1 MHz for 5s. By using virus-
loaded microbubbles, ultrasound facilitated the delivery
of viral vectors in a restricted area of cells exposed to
≥ 0.4 MPa peak-negative acoustic pressure. It showed that
the technology was an ideal mean suited for targeted
delivery.
The mechanism how ultrasound enhances the trans-
fection rate of transgene may be that ultrasound imparts
a microjet to the cell and facilitates local delivery of the
DNA into the cell. It also presumedly that ultrasound af-
fected cell regulatory or transcription factors. However,
the precise mechanism accounting for why expose ultra-
sound to cells together with and also to viral vector en-
hance the gene expression level is still blurred. Specific
studies should be conducted to explain these different
mechanisms and decide how UTMD influences AAV-
mediated gene expression. Therefore, Geers et al. [55]
have undertaken a study to interpret the mechanisms
behind how the combination of UTMD and AAV medi-
ated gene therapy work. They made use of “non-active
AAV”, which are AAV vectors chemically modified at
their surface with a poly (ethylene glycol) (PEG) brush,
and found the “non-active AAV” could be delivered in
the cytosol of cells directly through sonoporation. Thus
UTMD can specifically and effectively increase rAAV
gene delivery system, and it may afford potential for
highly effective gene delivery means for gene therapy of
cardiovascular diseases.Delivery gene to cardiovascular system by ultrasound and
novel microbubble
Compared with the other groups, the application of viral
vector significantly increased transgene expression, but
the toxicity and immunogenicity of the viral vectors still
plagued people. The non-viral vectors can enhance the
gene transfection rate. Noninvasive UTMD enable the
successful transfection of vascular endothelial grow factor
(VEGF), stem cell factor or other genes into the infracted
heart, thus increasing density of blood vessel, myocardial
perfusion and ventricular function. UTMD-mediated plas-
mid gene delivery takes advantage of myocardial contrast
echocardiography and has numerous merits including low
toxicity, lack of immunogenicity, and the potential for re-
petitive and targeted application [56,57]. However, there
were some injured endothelial cells in part of the vessel
wall with the ultrasound exposure. Also, Huang et al. [57]
developed new liposomes that could be used to protect
and transfer a bioactive gas to target in conjugate with
noninvasive UTMD. The results showed that it hold po-
tential for gas delivery and could be used to control thera-
peutic gas release (Figure 5).
Despite the existence of many in vitro experimental
studies on gene therapy with combination of non-viral
vectors and UTMD, research on in vivo therapeutic ap-
plication is on the beginning. Saliba et al. [58] developed
an interesting safe method for local gene transfer by in-
jection of plasmid or siRNA mixed with a standard com-
mercial liposome, with the presentence of ultrasound
Figure 5 Nitric oxide (NO) was delivered to the cultured vascular smooth muscle cells by ELIP with or without NO-scavenging agent,
haemoglobin. Vascular smooth muscle cells were transfected with a fluorescent probe, diaminofluorescein-2 diacetate (DFA-2DA), which reacts
with NO to produce a fluorescent signal. In the absence of haemoglobin, A: the cultured cells were treated with free NO and in the absence of
haemoglobin; B: the cultured cells were treated with NO encapsulated in ELIP. In the presence of haemoglobin, C: the cultured cells were treated
with free NO; D: the cultured cells were treated with NO encapsulated in ELIP. NO-loaded ELIP were able to efficiently deliver NO into cultured
cells even in the presence of a potent NO-scavenging agent such as haemoglobin [57].
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5min, another 5min), resulted in much higher transfection
efficiency. Zhao et al. [59] investigated that the cardio pro-
tective effect of the acidic fibroblast growth factor (aFGF)
combing with heparin modified microbubbles (aFGF-
HMB) under UTMD technique. Echocardiography of the
heart parenchyma was enhanced after aFGF-HMB injec-
tion. From ultrasonography, aFGF-HMB suspension had
good capability in heart ultrasonic contrast imaging.
As shown in M-mode echocardiography, the group
(aFGF-HMB + US) could remarkably stimulate myocardial
vessel neogenesis, resulting in a significant improvement
of regional as well as global myocardial contractile func-
tions (Figure 6).
Recently, Fujii et al. [41] used UTMD to deliver an-
giogenic genes. The result showed that GFP expression
was identified in the hearts of mice that were injected
with microbubble/GFP expressing plasmid complex five
days after UTMD and confirmed that successful in vivo
transfection was achieved by using the microbubble
technique (Figure 7). Sun et al. [60] prepared a cationic
microbubble with DNA-binding to improve targetedgene transfection of the ischemic heart for cardiac re-
generation. Compared its DNA-carrying capacity and
reporter gene transfection efficiency with the commer-
cially available Definity microbubble, the cationic
microbubbles loaded 70% more plasmid DNA than the
Definity microbubbles and UTMD was able to deliver
the therapeutic gene to the ischemic rat myocardium
and evaluated the effects on apoptosis, angiogenesis,
and cardiac function, and provided an efficient platform
for gene therapy of the ischemic heart and preserve car-
diac function (Figure 8).
Atherosclerosis is an inflammatory disease of the vas-
culature and risks, which can lead to heart attacks and
stroke, so there is a great need for both drug delivery
and detection of disease state. Phillips et al. [61] devel-
oped the novel microbubbles targeted to vascuolar cell
adhesion molecule 1 (VCAM-1), which can be used for
simultaneous ultrasound molecular imaging and gene
delivery. Compared with nontargeted microbubbles,
VCAM-1-targeted microbubbles exhibited a 100-fold in-
crease in adhesion to inflamed SMCs. Their studies may
aid in the detection and treatment of in-stent restenosis
Figure 6 M-mode echocardiography of Group (aFGF-HMB + US) [59].
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quently would realize gene or drug therapy to inflamed
vasculature.
A body of laboratory work has demonstrated that
UTMD was a promising tool for the local delivery of genes
and drugs [62]. A novel and potential site-specific gene
transfer, combination of ultrasound (1 MHz, 1.5 w/cm2,
10 minutes) and nanopackaged t-PA (Tissue plasminogenFigure 7 Confocal microphotograph of myocardial tissue of mice afte
UTMD. 5 days after the treatment of UTMD in the myocardial tissue of mic
fluorescent protein (GFP, green), nuclear staining (Hoechst, blue). A ~ C: co
group, the mice was injected with plasmids expressing GFP; G ~ I: the mer
Magnification _400 in A to F. Framed areas in D to F are shown enlarged aactivator, t-PA) gene plasmid, was also employed to cure
human thrombosis-related diseases. The results showed
that the heart ultrasound visualization increased obviously
compared to preinjection, and the baseline image follow-
ing the ultrasound treatment decreased after the intraven-
ous injection of microbubbles loaded with nanopackaged
t-PA gene plasmid [63]. Additionally, Ren et al. [64]
reported the preparation of three groups of self-mader treatment to show the efficiency of gene transfection in vivo by
e, the samples were immunostained with an antibody against green
ntrol group, the mice was injected with empty plasmids; D ~ I: GFP
ged images indicated co-localization of GFP and Hoechst.
t _600 in G to I [41].
Figure 8 Images of rats receiving luciferase plasmid delivered by UTMD. Bioluminescence was significantly higher at 3, 7, and 14 days after
gene delivery with the CMB compared with the Definity MB [60].
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10 uPA-MBs) via freeze-drying methods to achieve a more
efficacious and safer thrombolytic effect. It can be used for
thrombolysis when combined with low-frequency US
in vitro. The loaded uPA exhibited bioactivity by agarose
fibrin plate when exposed to US and in vitro thrombolysis
also showed higher effects with US exposure related to the
group who received uPA-MBs alone, the control group or
the US group. In conclusion, the physiochemical proper-
ties of these self-made uPA-MBs allow for intravenous in-
jection but 1 uPA-MB and 5 uPA-MBs are better than 10
uPA-MBs. The combination of uPA-MBs and US can
minish the in vitro dosage of uPA for thrombolysis
(Figure 9). Mannell et al. [65] loaded the magnetic (MNP)
perfluorocarbon-filled lipid microbubbles with lentiviral
particles and associated magnetic targeting of these com-
plexes with UTMD. The combination eventually led to a
transduction efficiency increase by 30-fold over the appli-
cation of naked virus alone.Application of ultrasound and microbubble in RNA
interference based gene therapy for cardiovascular
desease
RNA interference (RNAi) is a technique that could in-
hibit target gene expression based on sequence-specific
gene silencing using small interfering RNA (siRNA) [66].
The technique has attracted much attention for clinical
use in various diseases, and has potential to treat cardio-
vascular diseases. However, transfection of the endothe-
lium and myocardial cell with siRNAs in vivo still poses
a distinct hurdle [67]. There still need a noninvasive and ef-
fective method to transfer siRNA into target cells. Kinoshita
et al. [68] demonstrated that delivery siRNA intracellularly
via microbubble-enhanced focused ultrasound was viable,
and represented a powerful tool for using siRNA in vivo
and possibly in the clinical setting.
Among the more common approaches employed for
siRNA delivery are the use of ultrasound-microbubble
which can effectively delivery siRNAs into target areas
Figure 9 After treatment, the thrombi were observed under the electron microscope. A1, A2: control group; B1, B2: uPA group; C1, C2,
C3, C4: uPA + US group; A1, B1, C1, C3 were amplified by 1000 times; A2, B2, C2, C4 were amplified by 4000 times [64].
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microbubble complexes (a fluorescein-labeled siRNA, green
fluorescent protein (GFP) siRNA, and intercellular adhesion
molecule (ICAM)-1 siRNA), and confirmed that ICAM-1
siRNA/microbubble has the potential to suppress arter-
ial neointimal formation using ultrasound-microbubble
method (Figure 10). With ultrasound irradiation, siRNA/
microbubble is potent for clinical treatment of cardiovas-
cular diseases and other inflammatory disease.
Stem Cell Transplant for Treatment of Cardiovascular
Diseases Mediate by Ultrasound and Microbubble
Cell-based therapy presents an attractive approach to res-
toration of a functional endothelium and myocardium.After acute myocardial infarction, migration of bone
marrow-derived mesenchymal stem cells (MSCs) to vital
myocardium is a promising therapeutic method. Ultra-
sound irradiation inducing stimulation of microbubbles al-
lows locoregional pre-treatment of target tissue, and
combination of ultrasound irradiation and stem cell tech-
nology may improve transplantation efficacy and targeting
of MSCs, and enhance the efficacy of a sustained myocar-
dial cell delivery. Ghanem et al. [69] demonstrated that fo-
cused ultrasound with stimulated microbubbles improved
transplantation efficacy and allowed targeted engraftment
of MSCs. Compared to nontargeted areas, significantly
more MSCs adhered to the endothelium of targeted tis-
sues was observed, and they did not observe any apoptosis
Figure 10 Arteries harvested on day 28 stained with Elastica van Gieson (EvG). A: Significantly thickened intima in the arteries is seen with
ICAM-1 siRNA without ultrasound irradiation; B: B shows significant suppression of neointimal formation in the artery with ICAM-1 siRNA with
microbubble administration and ultrasound irradiation. C: VACM-1 siRNA had an effect statistically comparable to that of ICAM-1 siRNA in the
prevention of neointimal formation. D: The scrambled siRNA did not suppress neointimal formation [33].
Figure 11 DAPI positive cells were detected by fluorescent microscope. Compare with MSC infusion group, the US + Microbubble + MSC
group has much more DAPI-positive cells localized in the ischemic myocardium (A-B). MSCs were labeled with DAPI, and all the cells were dyed
in bright blue, and observed under light microscope (×200) and fluorescent microscope. (C) MSCs of US + Microbubble + MSC group (×100),
(D) MSC infusion group (×100) [56].
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Figure 12 The MSCs adherent to the aortic endoluminal surface after ultrasound mediated delivery survive and undergo
morphological changes (Scale bar = 100 mm), between 20min (two examples in A) 3h (B), and 24 h (C) post delivery [71].
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proved the feasibility of combination of ultrasound and
microbubbles for delivery of siRNA into MSC, and the re-
sults indicated that ultrasound and microbubble could
serve as a nonviral delivery method of siRNA into MSC,
which would be a useful appoach for regenerative medi-
cine in the future.
Moreover, MSCs conld be surface-coated electrostati-
cally with gas-filled lipid microbubbles (MB-MSCs) and
seeded to targeted areas or a specific vascular segment,
which is an emerging therapeutic option. Xu et al. [56]
launched experimental research to figure out whether
combining lipid-coated microbubbles with diagnostic US
could enable the site directed delivery of MSCs into the
myocardium even myocardial infarcted rabbits. After the
intravenous injection of lipid-coated microbubble ac-
company with BM-MSCs into the rabbits, the anterior
chest was treated with diagnostic ultrasound for 10 min
to induce infusion of BM-MSCs which was labeled with
DAPI in the nucleus. The results showed that DAPI
positive cells in myocardial infarction area were much
more than that of the MSCs infusion group (Figure 11).
Toma et al. [71] proposed a novel method by using
ultrasound-generated acoustic radiation force combined
with MB-MSCs to delivery of therapeutic cells to a spe-
cific endovascular treatment site. This approach may
be used for endoluminal cellular paving, providing a
powerful tool for cell-based gene delivery of injured ar-
terial segments (Figure 12).
Conclusions
Increasing evidences prove that UTMD is a promising
strategy to improve delivery efficiency, thus emerges as a
method with great promise for target-specific genedelivery. A variety of experiments have demonstrated
that the combination of UTMD and viral and non-viral
vectors in gene delivery could not only enhance the effi-
ciency of the viral vector, but also avoid its immunogen-
icity. Thus it may become a feasible, novel candidate for
gene therapy, providing support to gene therapy trial for
patients with cardiovascular diseases.
UTMD is a promising technique for gene delivery,
but most of its studies are in the preclinical stage.
UTMD still remains limited by its safety and efficiency.
Future work needs to be done before its clinical appli-
cation, including optimization of microbubble prepar-
ation technology to efficiently carry gene payloads
while maintaining acoustic activity, prolonging circula-
tion time to prevent clearance by the mononuclear cell,
improving targeting techniques to enhance tissue bind-
ing force in areas of high shear stress, and illustration
of optimal ultrasound parameters for each microbubble
and its intended application. What is more important,
as UTMD mediated gene therapy involve the multiple
interacting modalities, there needs to be close collabor-
ation between chemists, ultrasound engineers, and bi-
ologists to move this strategy to fruition.
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